9/21/2025

Discover AQR Capital's latest Q2 2025 portfolio moves—top holdings, stake increases, and insights on their quantitative investment strategy.

Source: SeekingAlpha

9/21/2025

Kenvue Inc. (NYSE:KVUE) is included among the 10 Best NYSE Dividend Stocks to Buy. Kenvue Inc. (NYSE:KVUE) produces and sells consumer health products across several categories, including over-the-counter medicines, personal care, and wellness items. Its portfolio features well-known household brands such as Tylenol for pain and fever relief, Neutrogena for skin care, and Listerine for oral […]

Source: Yahoo

9/21/2025

The trillion-dollar club will probably need to make room for at least one Dividend King in the coming years.

Source: Yahoo

9/21/2025

Johnson & Johnson (NYSE:JNJ) is included among the 12 Best Dividend Paying Stocks to Buy Now. Johnson & Johnson (NYSE:JNJ) is a major player in the pharmaceutical and medical device industries, with a recent market value close to $425 billion. The company is also showing growth, as second-quarter revenue increased 5.8% from the previous year […]

Source: Yahoo

9/20/2025

Amcor plc (NYSE:AMCR) is included among the 13 Incredibly Cheap Dividend Stocks to Invest in. Amcor plc (NYSE:AMCR), a global packaging leader, is shifting its focus from traditional commodity plastics to higher-margin healthcare and hygiene markets through an all-stock merger with Berry Global. The $13.8 billion deal, which includes more than $7 billion in assumed […]

Source: Yahoo

9/20/2025

In recent days, Johnson & Johnson announced a series of product milestones, including multiple new FDA approvals such as INLEXZO for bladder cancer and a subcutaneous induction regimen for TREMFYA in ulcerative colitis, alongside positive Phase 3 data for therapies targeting plaque psoriasis, multiple myeloma, and lung cancer. These developments, spanning both regulatory achievements and late-stage clinical successes, highlight the company's ongoing focus on innovative treatments addressing...

Source: Yahoo

9/20/2025

A high yield is only one part of the story when it comes to picking dividend stocks.

Source: Yahoo

9/19/2025

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) induction regimen of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC). With this approval, TREMFYA® is the first and only IL-23 inhibitor to offer both SC and intravenous (IV) induction options for the treatment of UC and Crohn's disease (CD), which combined affect approximately three million Americans.1 TREMFY

Source: Yahoo

9/19/2025

Health care stocks were mixed late Friday afternoon, with the NYSE Health Care Index easing 0.1% and

Source: Yahoo

9/19/2025

Regeneron unveiled what it calls "paradigm-shifting" test results for a drug that could prevent patients from developing multiple myeloma.

Source: Yahoo

9/19/2025

In MRD-evaluable patients, 100% achieved MRD negativity after six cycles of treatment.

Source: Yahoo

9/19/2025

With the Fed's first 2025 rate cut and upgraded growth outlook, ETFs in tech, financials, industrials and health care could benefit from momentum.

Source: Yahoo

9/19/2025

Merck eyes new launches like Capvaxive and Winrevair, among others, to drive long-term growth as Keytruda nears loss of exclusivity.

Source: Yahoo

9/19/2025

Johnson & Johnson (NYSE:JNJ) today announced that an investigational immune-based induction regimen with TECVAYLI® (teclistamab-cqyv) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) demonstrated meaningful clinical efficacy in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM).

Source: Yahoo

9/19/2025

MSFT, JNJ, NKE and SPGI use strong moats to fend off rivals and deliver consistent returns amid market shifts.

Source: Yahoo

9/19/2025

Johnson & Johnson announced on Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency had adopted a positive opinion recommending the approval of nipocalimab...

Source: Finnhub

9/19/2025

Shockwave Medical has been the only major player in the IVL market since 2015.

Source: Yahoo

9/19/2025

Johnson & Johnson has announced that the experimental combination of Tecvayli and Darzalex Faspro showed significant clinical efficacy in newly diagnosed patients with multiple myeloma who were...

Source: Finnhub

9/19/2025

AstraZeneca is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust pipeline. Click to read why AZN is a Buy.

Source: SeekingAlpha

9/19/2025

Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer commented on. Cramer discussed the stock’s momentum during the episode, as he said: “As of last night’s close, JNJ was the 10th best performing healthcare stock in the entire S&P 500, up 21.5% for the year. Now, if you’ve been paying attention to this […]

Source: Yahoo